RAW SEQUENCE LISTING

The Biotechnology Systems Branch of the Scientific and Technical

Application Serial Number: $\frac{09/647}{5\times 0000}$

ENTERED



IFW16

RAW SEQUENCE LISTING DATE: 02/10/2006
PATENT APPLICATION: US/09/647,457F TIME: 08:59:15

Input Set : A:\24390-01-26-06.txt

Output Set: N:\CRF4\02102006\1647457F.raw

```
3 <110> APPLICANT: Yeda Research and Development Company Ltd.
     5 <120> TITLE OF INVENTION: ASSAY FOR THE DIAGNOSIS OF SCHIZOPHRENIA BASED ON A NEW
PEPTIDE
     7 <130> FILE REFERENCE: 1276302
     9 <140> CURRENT APPLICATION NUMBER: 09/647,457F
C--> 10 <141> CURRENT FILING DATE: 2000-11-29
     12 <150> PRIOR APPLICATION NUMBER: PCT/IL99/00190
    13 <151> PRIOR FILING DATE: 1999-09-29
    15 <150> PRIOR APPLICATION NUMBER: 123925
    16 <151> PRIOR FILING DATE: 1998-04-02
     18 <160> NUMBER OF SEO ID NOS: 15
    20 <170> SOFTWARE: PatentIn version 3.3
    22 <210> SEQ ID NO: 1
    23 <211> LENGTH: 28
    24 <212> TYPE: PRT
    25 <213> ORGANISM: Artificial Sequence
    27 <220> FEATURE:
    28 <223> OTHER INFORMATION: being the immunologically active epitope
    31 <220> FEATURE:
    32 <221> NAME/KEY: MISC FEATURE
    33 <222> LOCATION: (1)..(1)
    34 <223> OTHER INFORMATION: Xaa(1) is S or absent
    36 <220> FEATURE:
    37 <221> NAME/KEY: MISC FEATURE
    38 <222> LOCATION: (1)..(11)
    39 <223> OTHER INFORMATION: provided that when Xaa(11) is absent, Xaa(1) through Xaa(10),
    40
              inclusive, are absent, and when Xaa(11) is D , Xaa(10) is A or
    41
              absent
    43 <220> FEATURE:
    44 <221> NAME/KEY: MISC FEATURE
    45 <222> LOCATION: (1)..(10)
    46 <223> OTHER INFORMATION: when Xaa(10) is absent, Xaa(1) through Xaa(9), inclusive, are
             absent, and when Xaa(10) is A, Xaa(9) is I or absent
    49 <220> FEATURE:
    50 <221> NAME/KEY: MISC FEATURE
    51 <222> LOCATION: (1)..(9)
    52 <223> OTHER INFORMATION: when Xaa(9) is absent, Xaa(1) through Xaa(8), inclusive, are
    53
              absent, and when Xaa(9) is I, Xaa(8) is F or absent
    55 <220> FEATURE:
    56 <221> NAME/KEY: MISC_FEATURE
    57 <222> LOCATION: (1)..(8)
    58 <223> OTHER INFORMATION: when Xaa(8) is absent, Xaa(1) through Xaa(7), inclusive, are
    59
              absent, and when Xaa(8) is F, Xaa(1) through Xaa(7) are,
    60
              respectively, S, G, E, T, E, D, and T
```

TIME: 08:59:15

```
Input Set : A:\24390-01-26-06.txt
                Output Set: N:\CRF4\02102006\1647457F.raw
62 <220> FEATURE:
63 <221> NAME/KEY: MISC_FEATURE
64 <222> LOCATION: (2)..(2)
65 <223> OTHER INFORMATION: Xaa(2) is G or absent
67 <220> FEATURE:
68 <221> NAME/KEY: MISC FEATURE
69 <222> LOCATION: (3)..(3)
70 <223> OTHER INFORMATION: Xaa(3) is E or absent
72 <220> FEATURE:
73 <221> NAME/KEY: MISC FEATURE
74 <222> LOCATION: (4)..(4)
75 <223> OTHER INFORMATION: Xaa(4) is T or absent
77 <220> FEATURE:
78 <221> NAME/KEY: MISC_FEATURE
79 <222> LOCATION: (5)..(5)
80 <223> OTHER INFORMATION: Xaa(5) is E or absent
82 <220> FEATURE:
83 <221> NAME/KEY: MISC FEATURE
84 <222> LOCATION: (6)..(6)
85 <223> OTHER INFORMATION: Xaa(6) is D or absent
87 <220> FEATURE:
88 <221> NAME/KEY: MISC FEATURE
89 <222> LOCATION: (7)...(7)
90 <223> OTHER INFORMATION: Xaa(7) is T or absent
92 <220> FEATURE:
93 <221> NAME/KEY: MISC FEATURE
94 <222> LOCATION: (8)..(8)
95 <223> OTHER INFORMATION: Xaa(8) is F or absent
97 <220> FEATURE:
98 <221> NAME/KEY: MISC_FEATURE
99 <222> LOCATION: (9)..(9)
100 <223> OTHER INFORMATION: Xaa(9) is I or absent
102 <220> FEATURE:
103 <221> NAME/KEY: MISC_FEATURE
104 <222> LOCATION: (10)..(10)
105 <223> OTHER INFORMATION: Xaa(10) is A or absent
107 <220> FEATURE:
108 <221> NAME/KEY: MISC FEATURE
109 <222> LOCATION: (19)..(19)
110 <223> OTHER INFORMATION: Xaa(19) is C, G, P
112 <220> FEATURE:
113 <221> NAME/KEY: MISC FEATURE
114 <222> LOCATION: (25)..(25)
115 <223> OTHER INFORMATION: Xaa(25) is A, P
117 <220> FEATURE:
118 <221> NAME/KEY: MISC FEATURE
119 <222> LOCATION: (25)..(28)
120 <223> OTHER INFORMATION: Xaa(28) is R or absent, provided that Xaa(25) and Xaa(26)
          taken together to form a sequence selected from the group
```

RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/647,457F

are

121

```
PATENT APPLICATION: US/09/647,457F
                                                           TIME: 08:59:15
                    Input Set : A:\24390-01-26-06.txt
                    Output Set: N:\CRF4\02102006\1647457F.raw
    122
              consisting of AP and PA
    124 <220> FEATURE:
    125 <221> NAME/KEY: MISC FEATURE
    126 <222> LOCATION: (26)..(26)
    127 <223> OTHER INFORMATION: Xaa(26) is P, A
    129 <400> SEQUENCE: 1
132 1
                       5
    135 Cys Thr Xaa Gln Ile Lys Thr Gly Xaa Xaa Cys Xaa
    139 <210> SEQ ID NO: 2
    140 <211> LENGTH: 28
    141 <212> TYPE: PRT
    142 <213> ORGANISM: Artificial Sequence
    144 <220> FEATURE:
    145 <223> OTHER INFORMATION: being the immunologically active epitope
    147 <400> SEQUENCE: 2
    149 Ser Gly Glu Thr Glu Asp Thr Phe Ile Ala Asp Leu Val Val Gly Leu
    150 1
    153 Cys Thr Gly Gln Ile Lys Thr Gly Ala Pro Cys Arg
    154
    157 <210> SEQ ID NO: 3
    158 <211> LENGTH: 16
    159 <212> TYPE: PRT
    160 <213> ORGANISM: Artificial Sequence
    162 <220> FEATURE:
    163 <223> OTHER INFORMATION: peptide capable of binding antibodies that are found in
elevated
              levels in body fluids of schizophrenic patients.
    164
    166 <400> SEQUENCE: 3
    168 Leu Val Val Gly Leu Cys Thr Cys Gln Ile Lys Thr Gly Pro Ala Cys
                                            10
    169 1
    172 <210> SEQ ID NO: 4
    173 <211> LENGTH: 20
    174 <212> TYPE: PRT
    175 <213> ORGANISM: Artificial Sequence
    177 <220> FEATURE:
    178 <223> OTHER INFORMATION: peptide capable of binding antibodies that are found in
elevated
              levels in body fluids of schizophrenic patients.
    179
    181 <400> SEQUENCE: 4
    183 Ile Ala Asp Leu Val Val Gly Leu Cys Thr Gly Gln Ile Lys Thr Gly
    184 1
    187 Ala Pro Cys Arg
    188
                    20
    191 <210> SEO ID NO: 5
    192 <211> LENGTH: 19
    193 <212> TYPE: PRT
    194 <213> ORGANISM: Artificial Sequence
    196 <220> FEATURE:
    197 <223> OTHER INFORMATION: peptide capable of binding antibodies that are found in
elevated
```

RAW SEQUENCE LISTING

```
PATENT APPLICATION: US/09/647,457F
                                                             TIME: 08:59:15
                     Input Set : A:\24390-01-26-06.txt
                     Output Set: N:\CRF4\02102006\1647457F.raw
               levels in body fluids of schizophrenic patients.
     198
    200 <400> SEQUENCE: 5
    202 Ala Asp Leu Val Val Gly Leu Cys Thr Gly Gln Ile Lys Thr Gly Ala
    203 1
                                              10
    206 Pro Cys Arg
    210 <210> SEQ ID NO: 6
    211 <211> LENGTH: 18
    212 <212> TYPE: PRT
    213 <213 > ORGANISM: Artificial Sequence
     215 <220> FEATURE:
    216 <223> OTHER INFORMATION: peptide capable of binding antibodies that are found in
elevated
    217
               levels in body fluids of schizophrenic patients.
     219 <400> SEQUENCE: 6
    221 Asp Leu Val Val Gly Leu Cys Thr Gly Gln Ile Lys Thr Gly Ala Pro
    222 1
                                             10
    225 Cys Arg
    229 <210> SEQ ID NO: 7
    230 <211> LENGTH: 17
    231 <212> TYPE: PRT
    232 <213> ORGANISM: Artificial Sequence
    234 <220> FEATURE:
    235 <223> OTHER INFORMATION: peptide capable of binding antibodies that are found in
elevated
    236
               levels in body fluids of schizophrenic patients.
    238 <400> SEQUENCE: 7
    240 Leu Val Val Gly Leu Cys Thr Gly Gln Ile Lys Thr Gly Ala Pro Cys
    241 1
    244 Arg
    248 <210> SEQ ID NO: 8
    249 <211> LENGTH: 17
    250 <212> TYPE: PRT
    251 <213> ORGANISM: Artificial Sequence
    253 <220> FEATURE:
    254 <223> OTHER INFORMATION: peptide capable of binding antibodies that are found in
elevated
               levels in body fluids of schizophrenic patients.
    257 <400> SEQUENCE: 8
    259 Leu Val Val Gly Leu Cys Thr Gly Gln Ile Lys Thr Gly Pro Ala Cys
    260 1
    263 Arg
    267 <210> SEQ ID NO: 9
    268 <211> LENGTH: 17
    269 <212> TYPE: PRT
    270 <213> ORGANISM: Artificial Sequence
    272 <220> FEATURE:
    273 <223> OTHER INFORMATION: peptide capable of binding antibodies that are found in
elevated
    274
               levels in body fluids of schizophrenic patients.
    276 <400> SEQUENCE: 9
    278 Leu Val Val Gly Leu Cys Thr Pro Gln Ile Lys Thr Gly Pro Ala Cys
    279 1
                         5
    282 Arg
```

RAW SEQUENCE LISTING

TIME: 08:59:15

PATENT APPLICATION: US/09/647,457F Input Set : A:\24390-01-26-06.txt Output Set: N:\CRF4\02102006\1647457F.raw 286 <210> SEQ ID NO: 10 287 <211> LENGTH: 20 288 <212> TYPE: PRT 289 <213> ORGANISM: Artificial Sequence 291 <220> FEATURE: 292 <223> OTHER INFORMATION: peptide capable of binding antibodies that are found in elevated levels in body fluids of schizophrenic patients. 293 295 <400> SEQUENCE: 10 297 Ser Gly Glu Thr Glu Asp Thr Phe Ile Ala Asp Leu Val Val Gly Leu 298 1 301 Cys Thr Gly Gln 302 20 305 <210> SEQ ID NO: 11 306 <211> LENGTH: 16 307 <212> TYPE: PRT 308 <213> ORGANISM: Artificial Sequence 310 <220> FEATURE: 311 <223> OTHER INFORMATION: peptide capable of binding antibodies that are found in elevated levels in body fluids of schizophrenic patients. 312 314 <400> SEQUENCE: 11 316 Val Val Gly Leu Cys Thr Gly Gln Ile Lys Thr Gly Ala Pro Cys Arg 317 1 10 320 <210> SEO ID NO: 12 321 <211> LENGTH: 12 322 <212> TYPE: PRT 323 <213 > ORGANISM: Artificial Sequence 325 <220> FEATURE: 326 <223> OTHER INFORMATION: peptide capable of binding antibodies that are found in elevated levels in body fluids of schizophrenic patients. 327 329 <400> SEQUENCE: 12 331 Cys Thr Gly Gln Ile Lys Thr Gly Ala Pro Cys Arg 335 <210> SEQ ID NO: 13 336 <211> LENGTH: 16 337 <212> TYPE: PRT 338 <213> ORGANISM: Artificial Sequence 340 <220> FEATURE: 341 <223> OTHER INFORMATION: peptide capable of binding antibodies that are found in elevated levels in body fluids of schizophrenic patients. 342 344 <400> SEQUENCE: 13 346 Leu Val Val Gly Leu Cys Thr Gly Gln Ile Lys Thr Gly Ala Pro Cys 10 350 <210> SEQ ID NO: 14 351 <211> LENGTH: 15 352 <212> TYPE: PRT 353 <213> ORGANISM: Artificial Sequence 355 <220> FEATURE: 356 <223> OTHER INFORMATION: peptide capable of binding antibodies that are found in elevated

RAW SEQUENCE LISTING

357 levels in body fluids of schizophrenic patients.

RAW SEQUENCE LISTING ERROR SUMMARY PATENT APPLICATION: US/09/647,457F

DATE: 02/10/2006 TIME: 08:59:16

Input Set : A:\24390-01-26-06.txt

Output Set: N:\CRF4\02102006\I647457F.raw

Please Note:

Use of n and/or Xaa have been detected in the Sequence Listing. Please review the Sequence Listing to ensure that a corresponding explanation is presented in the <220> to <223> fields of each sequence which presents at/least one n or Xaa.

Seq#:1; Xaa Pos. 1,2,3,4,5,6,7,8,9,10,11,19,25,26,28

VERIFICATION SUMMARY

PATENT APPLICATION: US/09/647,457F TIME: 08:59:16

DATE: 02/10/2006

Input Set : A:\24390-01-26-06.txt

Output Set: N:\CRF4\02102006\I647457F.raw

L:10 M:271 C: Current Filing Date differs, Replaced Current Filing Date L:131 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:1 after pos.:0

M:341 Repeated in SeqNo=1